Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder

International Clinical Psychopharmacology

Volumn 15, Issue 3, 2000, Pages 153-161

  Broocks, A ^b   Bandelow, B ^a   George, A ^a   Jestrabeck, C ^a   Opitz, M ^a   Bartmann, U ^a   Gleiter, C H ^a   Meineke, I ^a   Roed, I S ^a   Ruther E ^a   Hajak, G ^a  

^a Bayer Tropon ^*

^b UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Agoraphobia; Anxiety; Ipsapirone; m chlorophenylpiperazine; Panic disorder; Serotonin

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; HYDROCORTISONE; IPSAPIRONE; NORADRENALIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2C RECEPTOR;

ADULT; AGORAPHOBIA; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHERMIA; MAJOR CLINICAL STUDY; MALE; NORADRENALIN BLOOD LEVEL; PANIC; PRIORITY JOURNAL;

EID: 0034116447     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015030-00004     Document Type: Article

References (50)

1. Aulakh CS, Hill JL, Murphy DL (1988) A comparison of feeding and locomotion responses to serotonin agonists in three rat strains. Pharmacol Biochem Behav 31:567-571.
2. Aulakh CS, Hill JL, Murphy DL (1992) Effects of various serotonin receptor subtype-selective antagonists alone and on m-chlorophenylpiperazine-induced neuroendocrine changes in rats. J Pharmacol Exp Ther 263:588-595.
3. Bagdy G, Szemeredi K, Kanyicska B, Murphy DL (1989) Different serotonin receptors mediate blood pressure, heart rate, plasma catecholamine and prolactin responses to m-chlorophenylpiperazine in conscious rats. J Pharmaco Exp Ther 250:72-78.
4. Bandelow B (1995) Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. Int Clin Psychopharmacol 10:73-81.
5. Broocks A, Briggs NC, Pigott TA, Hill JI, Canter SK, Tolliver TJ, et al. (1997) Behavioral, physiological and neuroendocrine responses in healthy volunteers to m-chlorophenylpiperazine (m-CPP) with and without ondansetron pretreatment. Psychopharmacology (Berl) 130:91-103.
6. Broocks A, Meyer TF, Bandelow B, et al. (1997) Exercise avoidance and impaired endurance capacity in patients with panic disorder. Neuropsychobiology 36:182-187.
7. Broocks A, Bandelow B, Pekrun G, George A, Meyer T, Bartmann U, et al. (1998) Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry 155:603-609.
8. Broocks A, Pigott TA, Hill JL, Canter S, Grady TA, L'Hereux F, Murphy DL (1998) Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results [in process citation]. Psychiatry Res 79:11-20.
9. Broocks A, Meyer T, George A, Hillmer-Vogel U, Meyer D, Bandelow B, et al. (1999) Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners. Neuropsychopharmacology 20:150-161.
10. Cameron OG, Smith CB, Hollingsworth PJ, Nesse RM, Curtis GC (1984) Platelet alpha 2-adrenergic receptor binding and plasma catecholamines. Before and during imipramine treatment in patients with panic anxiety. Arch Gen Psychiatry 41:1144-1148.
11. Cameron OG, Smith CB, Lee MA, Hollingsworth PJ, Hill EM, Curtis GC (1990) Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 28:3-20.
12. Charney DS, Heninger GR (1986) Abnormal regulation of noradrenergic function in panic disorders. Arch Gen Psychiatry 43:1042-1054.
13. Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144:1030-1036.
14. Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 9:14-24.
15. Dajas F, Nin A, Barbeito L (1986) Urinary norepinephrine excretion in panic and phobic disorders. J Neural Transm 65:75-81.
16. De Vry J, Glaser T, Schuurmann T, Schreiber R, Traber J (1991) 5-HT1A receptors in anxiety. In: New Concepts in Anxiety (Briley M, ed), London: McMillan Press.
17. Ehlers A, Breuer P (1992) Increased cardiac awareness in panic disorder. J Abnorm Psychol 101:371-382.
18. Ehlers A, Breuer P, Dohn D, Fiegenbaum W (1995) Heartbeat perception and panic disorder: possible explanations for discrepant findings. Behav Res Ther 33:69-76.
19. Germine M, Goddard AW, Sholomskas DE, Woods SW, Charney DS, Heninger GR (1994) Response to meta-chlorophenylpiperazine in panic disorder patients and healthy subjects: influence of reduction in intravenous dosage. Psychiatry Res 54:115-133.
20. Goa KL, Ward A (1986) Buspirone. A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic. Drugs 32:114-129.
21. Hamilton M (1969) Diagnosis and rating of anxiety. Br J Psychiatr Spec 3:76-79.
22. Kahn RS, Wetzler S (1991) m-Chlorophenylpiperazine as a probe of serotonergic function. Biol Psychiatry 30:1139-1166.
23. Kahn RS, Asnis GM, Wetzler S, van Praag HM (1988) Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology Berl 96:360-364.
24. Kahn RS, Wetzler S, van Praag HM, Asnis GM, Strauman T (1988) Behavioral indications for serotonin receptor hypersensitivity in panic disorder. Psychiatry Res 25:101-104.
25. Kahn RS, Trestman R, Lawlor BA, Gabriel S, Davidson M, Siever L (1994) Effects of ipsapirone in healthy subjects: a dose-response study. Psychopharmacology Berl 114:155-160.
26. Klein DF (1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 50:306-317.
27. Kuboki T, Suematsu H (1992) [Panic disorder]. Nippon Rinsho 50:2773-2782.
28. Lesch KP (1992) 5-HT1A receptor responsivity in anxiety disorders and depression. Prog Neuropsychopharmacol Biol Psychiatry 723-733.
29. Lesch KP, Rupprecht R, Poten B, et al. (1989) Endocrine responses to 5-hydroxytryptamine-1A receptor activation by ipsapirone in humans. Biol Psychiatry 26:203-205.
30. Lesch KP, Mayer S, Disselkamp Tietze J, Hoh A, Wiesmann M, Osterheider M, Schulte HM (1990) 5-HT1A receptor responsivity in unipolar depression. Evaluation of ipsapirone-induced ACTH and cortisol secretion in patients and controls. Biol Psychiatry 28:620-628.
31. Lesch KP, Wiesmann M, Hoh A, Muller T, Disselkamp-Tietze J, Osterheilder M, Schulte HM (1992) 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology Berl 106:111-117.
32. Liebowitz MR, Fyer AJ, Gorman JM, et al. (1984) Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry 41:764-770.
33. Liebowitz MR, Gorman JM, Fyer AJ, Levitt M, Dillon D, Levy G, et al. (1985) Lactate provocation of panic attacks. II. Biochemical and physiological findings. Arch Gen Psychiatry 42:709-719.
34. Martinsen EW, Strand J, Paulsson G, Kaggestad J (1989) Physical fitness level in patients with anxiety and depressive disorders. Int J Sports Med 10:58-61.
35. Miyakoda H, Kitamura H, Kinuguwa T, Saito M, Kotake H, Mashiba H (1990) Cardiac neurosis: exercise tolerance and the role of sympathetic activity. Jpn J Med 29:493-499.
36. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM (1989) Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacol Berl 98:275-282.
37. Murphy DL, Lesch KP, Aulakh CS, Pigott TA (1991) Serotonin-selective arylpiperazines with neuroendocrine, behavioral, temperature, and cardiovascular effects in humans. Pharmacol Rev 43:527-552.
38. Nesse RM, Cameron OG, Curtis GC, McCann DS, Huber Smith MJ (1984) Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 41:771-776.
39. Nesse RM, Curtis GC, Thyer BA, McCann DS, Huber Smith MJ, Knopf RF (1985) Endocrine and cardiovascular responses during phobic anxiety. Psychosom Med 47:320-332.
40. NIMH (1976) Clinical global impressions. In: Assessment Manual For Psychopharmacology (Guy W, ed), Rockville, Maryland: NIMH. pp. 217-222.
41. Papp LA, Klein DF, Gorman JM (1993) Carbon dioxide hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry 150:1149-1157.
42. Pirke KM, Schweiger U, Lemmel W, Krieg JC, Berger M (1985) The influence of dieting on the menstrual cycle of healthy young women. J Clin Endocrinol Metabol 60:1174-1179.
43. Pitts N, McClure JN (1967) Lactate metabolism in anxiety neurosis. New Engl J Med 277:1329-1336.
44. Pohl R, Yeragani VK, Balon R (1990) Effects of isoproterenol in panic disorder patients after antidepressant treatment. Biol Psychiatry 28:203-214.
45. SAS (1989) SAS User's Guide. Cary, NC: SAS Institute Inc.
46. Schneider P, Evans L, Ross Lee L, Wiltshire B, Eadie M, Kenardy J, Hoey H (1987) Plasma biogenic amine levels in agoraphobia with panic attacks. Pharmacopsychiatry 20:102-104.
47. Schwartz PJ, Wehr TA, Rosenthal NE, Bartko JJ, Oren DA, Luetke C, Murphy DL (1995) Serotonin and Thermoregulation. Neuropsychopharmacology 13:105-115.
48. Targum SD (1992) Cortisol response during different anxiogenic challenges in panic disorder patients. Psychoneuroendocrinology 17:453-458.
49. Uhde TW, Tancer ME, Rubinow DR, Roscow BD, Boulenger J-P, Vittone B, et al. (1992) Evidence for hypothalamo-growth hormone dysfunction in panic disorder: profile of growth hormone (GH) responses to clonidine, yohimbine, caffeine, glucose, GRF and TRH in panic disorder patients versus healthy volunteers. Neuropsychopharmology 6:101-118.
50. Villacres EC, Hollifield M, Katon WJ, Wilkinson CW, Veith RC (1987) Sympathetic nervous system activity in panic disorder. Psychiatry Res 21:313-321.